🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — July 11, 2026

The July 11, 2026 approval stream is dominated by 5 biosimilar/fallback approvals and 1 NME, presenting a mixed but actionable picture for biotech investors. The standout event is VERA THERAPEUTICS INC.'s NME approval for ATACIEPT-VYMJ (TRUTAKNA) under Priority Review, a clear bullish signal for the sponsor given the high approval bar and expedited review. The remaining 5 approvals are neutral biosimilar entries for established molecules (DESOGESTREL, DIMETHYL SULFOXIDE, MORPHINE SULFATE, VARENICLINE TARTRATE, NITROGLYCERIN) from small-cap sponsors like ANNORA PHARMA, STIRA, QUAGEN, SOMERSET THERAPS LLC, and PADAGIS ISRAEL, which lack disclosed commercial data and face intense generic competition. The key risk is the lack of differentiation and pricing power for these biosimilars, while the primary opportunity is VERA's NME launch trajectory and potential market creation. No dominant therapeutic area theme emerges, but the concentration of biosimilar approvals signals ongoing commoditization in legacy drug markets.

6 total filings
· daily

NME Blockbuster Approvals — July 11, 2026

This single-approval period features one NME approval—ATACIEPT-VYMJ (TRUTAKNA) from VERA THERAPEUTICS INC.—granted under Priority Review. No biosimilars or label expansions were approved, making this a focused, high-conviction event for VERA. The dominant theme is a novel therapeutic entry with regulatory priority, signaling strong unmet need. The highest-conviction signal is the NME approval itself, which provides VERA with 5-year NCE data exclusivity and a potential commercial catalyst. Key risk is the lack of disclosed commercial data (peak sales, pricing, market position), which limits near-term revenue visibility for investors.

1 total filings
· daily

New Drug Approvals (Original) — July 11, 2026

During the period of July 11, 2026, the FDA approved 6 new drug applications, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 6 'Other' approvals (primarily biosimilar-type fallback approvals). The most significant event is the NME approval of ATACIEPT-VYMJ (TRUTAKNA) by VERA THERAPEUTICS INC., which received Priority Review and represents the sole bullish signal. The remaining five approvals are neutral biosimilar or generic-type entries for DESOGESTREL (ANNORA PHARMA), DIMETHYL SULFOXIDE (STIRA), MORPHINE SULFATE (QUAGEN), VARENICLINE TARTRATE (SOMERSET THERAPS LLC), and NITROGLYCERIN (PADAGIS ISRAEL). No dominant therapeutic area theme emerged, as the approvals span contraception, pain, smoking cessation, and cardiovascular indications. Key watch items include the commercial launch trajectory of TRUTAKNA and potential competitive dynamics in the smoking cessation market from the VARENICLINE TARTRATE approval.

6 total filings
· daily

DHS Homeland Security Contracts — July 11, 2026

The single contract analyzed, a $98.7 million firm-fixed-price delivery order from the Department of Homeland Security (DHS) to Smiths Detection Inc., underscores a civilian security screening theme with zero defense exposure. The award is non-competitive, suggesting Smiths Detection holds a proprietary or incumbent position for TSA explosive detection systems, providing revenue visibility through August 2027. However, only $42.4 million has been outlayed, leaving $56.3 million in future obligations subject to budget execution risk under a potential Continuing Resolution. The neutral signal strength (5/10) reflects balanced risk-reward: predictable fixed-price revenue offset by medium pricing risk and lack of competitive validation. Key watch items include TSA's future solicitation strategy and Smiths Detection's cost performance on this fixed-price contract.

1 total filings
· daily

New Federal Contractors — July 11, 2026

The single contract recorded for July 11, 2026, is a $98.7 million sole-source delivery order from the Transportation Security Administration (TSA) to Smiths Detection Inc., a foreign-owned manufacturer of explosive detection systems. This civilian award accounts for 100% of the period's total obligation, with no defense-related contracts in the stream. The highest-conviction signal is Smiths Detection's non-competitive position, suggesting a durable incumbent relationship with TSA, though only $42.4 million has been outlayed, leaving $56.3 million in future obligations at risk under a continuing resolution. Key risks include fixed-price execution pressure on margins and the lack of competitive validation for pricing. The neutral signal strength (5/10) reflects a stable but unexciting single-award profile.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 11, 2026

This digest covers a single $98.7 million civilian contract modification awarded to Smiths Detection Inc. by the Department of Homeland Security (TSA) for medium-speed explosive detection systems. The contract is a firm-fixed-price delivery order, awarded non-competitively, signaling an incumbent or sole-source position. With $42.4 million already outlayed and the remainder due through August 2027, the award provides multi-year revenue visibility but carries medium pricing risk. The key signal is neutral, reflecting a stable, non-competitive renewal in a mature security screening market. Investors should watch for future TSA competitive solicitations that could challenge Smiths Detection's incumbent position.

1 total filings
· daily

Contract Deobligations Alert — July 11, 2026

This digest covers a single $98.7 million civilian contract deobligation from the Department of Homeland Security to Smiths Detection Inc., a foreign-owned manufacturer of explosive detection systems. The award is a firm-fixed-price delivery order from the Transportation Security Administration for medium-speed explosive detection systems, with $42.4 million already outlayed and $56.3 million in potential future obligations through August 2027. The contract was awarded non-competitively, suggesting an incumbent or sole-source position, which is a moderately bullish signal for Smiths Detection's revenue visibility. However, the neutral signal strength (5/10) and medium pricing risk reflect the fixed-price nature of the contract, which could compress margins if costs rise. Key watch items include future TSA solicitations for competitive dynamics and Smiths Detection's cost performance on this fixed-price contract.

1 total filings
· daily

Contract Option Exercises — July 11, 2026

The single contract option exercise analyzed for July 11, 2026, totals $98.7 million, entirely civilian (Department of Homeland Security/TSA), with no defense-related awards. The sole award to Smiths Detection Inc. for medium-speed explosive detection systems reflects a non-competitive, sole-source follow-on arrangement, signaling an entrenched incumbent position in TSA security screening. The highest-conviction signal is the neutral-to-bullish moat implied by the lack of competition, though the fixed-price structure introduces execution risk. A key watch item is the $56.3 million in un-outlayed funds through August 2027, which could be vulnerable to budget shifts or contract protests.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 11, 2026

The single high-value federal grant analyzed for July 11, 2026, totals $98.7 million, entirely civilian (Department of Homeland Security/TSA), with no defense-related awards. The dominant theme is continued investment in aviation security screening technology, specifically explosive detection systems. The highest-conviction signal is Smiths Detection's sole-source, firm-fixed-price delivery order, which suggests an entrenched incumbent position but carries medium execution risk due to fixed-price cost overrun exposure. A key watch item is the $56.3 million in unfunded future obligations through August 2027, which could be vulnerable under a potential Continuing Resolution or budget reallocation.

1 total filings
· daily

General Federal Contracts — July 11, 2026

This single-contract digest covers a $98.7 million civilian award from the Department of Homeland Security (TSA) to SMITHS DETECTION INC. for medium-speed explosive detection systems, with zero defense-related contracts. The dominant theme is continued investment in aviation security screening technology, driven by TSA’s non-competitive procurement from an established incumbent. The highest-conviction signal is the sole-source nature of the award, which underscores SMITHS DETECTION’s entrenched position but also limits competitive visibility. Key risks include fixed-price execution pressure on margins and the $56.3 million in unfunded future obligations that depend on budget continuity and TSA priorities.

1 total filings
· daily

Federal Construction & Infrastructure Contracts — July 10, 2026

This digest covers $202.1 million in federal construction and infrastructure contracts awarded between July 2025 and July 2026, all from civilian agencies (0% defense-related). The Department of Veterans Affairs is the dominant spender, accounting for three of five awards totaling $124.9 million (62% of aggregate), specifically for EHRM infrastructure upgrades and boiler plant construction—signaling sustained investment in aging healthcare facility modernization. The highest-conviction signal is the full upfront obligation of the $34.7 million AMVET SCHLOSSER JV contract, which provides immediate revenue visibility but carries high execution risk due to fixed-price pricing. The most notable risk is that all five contracts are firm-fixed-price with high execution risk, and aggregate outlays to date are only $4.4 million (2.2% of total), indicating early-stage performance and potential margin compression for small contractors.

5 total filings
· daily

VA Healthcare & Services Contracts — July 10, 2026

This digest synthesizes four VA healthcare and services contracts totaling $314.2 million, all civilian (0% defense), awarded primarily between September 2025 and July 2026. The dominant theme is VA facility modernization, with three Service-Disabled Veteran-Owned Small Business (SDVOSB) construction awards for Electronic Health Record Modernization (EHRM) and boiler plant upgrades totaling $124.9 million, signaling stable but non-growth-driven infrastructure spending. The highest-conviction signal is Guidehouse LLP's $189.3 million management consulting BPA call, a full-and-open competitive win with near-maximum funding ($0 outlayed) that suggests strong initial positioning but zero revenue recognized to date. Key risk: all four contracts carry fixed-price risk, and three are SDVOSB set-asides with limited competitive moats and no tracked outlays, raising execution and margin concerns.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 10, 2026

The sole contract in this digest is a $87.1 million cost-plus-fixed-fee delivery order awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., by the NIH National Cancer Institute for operational support of the NIAID VRC. This is a civilian health R&D award with no defense-related content, reflecting sustained NIH funding for biomedical research services. The neutral signal (strength 5/10) reflects competitive win strength offset by limited near-term revenue visibility, as only 25% of the total has been outlaid. Key risk is the short base period ending August 2026, making option exercise a critical watch item for revenue continuity.

1 total filings
· daily

New Federal Contractors — July 10, 2026

This digest of 18 federal contracts, totaling $1.85 billion in obligations, reveals a heavily civilian-dominated procurement environment with only one defense-related award (HII Mission Technologies Corp at $933.5M). The aggregate is skewed by a single massive, cost-plus-award-fee delivery order to HII for remote sensing support, which constitutes over 50% of total value and is the only bullish signal. The remaining 17 contracts are neutral, spread across civilian agencies (VA, HHS, USDA, GSA, EPA, DOI, DOL, SSA, USAID) with a strong theme of healthcare infrastructure modernization (VA EHRM upgrades, NIH biomedical research) and wildfire suppression aviation (three awards to 10 Tanker Air Carrier totaling ~$104M). Key risks include execution risk on fixed-price construction contracts (VA EHRM upgrades, NPS bathhouse rehab) and budget uncertainty for discretionary USAID and USDA Forest Service programs. The highest-conviction signal is the HII win, which strengthens its competitive moat in defense R&D services, but investors should watch for option exercises on the JCETII program to confirm sustained demand.

18 total filings
· daily

Significant Contract Modifications ($10M+) — July 10, 2026

This digest of 18 significant contract modifications totaling $1.85 billion reveals a civilian-agency-dominated procurement landscape, with only one defense-related award (HII Mission Technologies' $933.5M GSA delivery order) accounting for over half the aggregate value. The remaining $913 million is spread across 17 civilian contracts from agencies including VA, HHS, USDA, EPA, and DOI, signaling robust non-defense federal spending on IT modernization, healthcare infrastructure, and environmental remediation. The highest-conviction signal is the HII award, which strengthens Huntington Ingalls Industries' competitive position in defense R&D services, though its cost-plus pricing limits margin upside. Key risks include execution pressure from multiple firm-fixed-price construction contracts (VA, DOI, GSA) and the concentration of three separate awards to 10 Tanker Air Carrier ($104M total) for wildfire suppression, creating revenue dependency for a private entity. The digest shows no bearish signals, but the neutral-to-bullish tilt masks execution risk in fixed-price infrastructure work and the vulnerability of civilian agency spending to continuing resolution uncertainty in Q4 2026.

18 total filings
· daily

Contract Deobligations Alert — July 10, 2026

This digest of 18 government contracts, totaling $1.85 billion in obligations, reveals a predominantly civilian-driven procurement landscape with only one defense-related award. The dominant theme is infrastructure modernization, particularly within the Department of Veterans Affairs (VA) and the General Services Administration (GSA), alongside niche awards for wildfire suppression and healthcare IT. The highest-conviction signal is the $933.5 million award to HII Mission Technologies Corp for remote sensing support, which is the sole bullish signal and highlights a competitive win in defense-related R&D. Key risks include execution risk on numerous firm-fixed-price construction contracts and the lack of outlays on several large awards, suggesting delayed revenue recognition. Investors should monitor the VA's EHRM program and GSA's building modernization pipeline for sustained civilian spending trends.

18 total filings
· daily

Contract Option Exercises — July 10, 2026

This digest of 18 contract option exercises, totaling $1.85 billion, is overwhelmingly civilian-focused with only one defense-related award. The dominant theme is federal infrastructure modernization, led by the Department of Veterans Affairs (VA) and General Services Administration (GSA), with notable spending on healthcare facility upgrades and building retrofits. The highest-conviction signal is HII Mission Technologies Corp's $933.5 million cost-plus-award-fee delivery order for JCETII remote sensing support, which strengthens Huntington Ingalls Industries' position in defense R&D services. Key risks include execution challenges on multiple firm-fixed-price construction contracts and the absence of defense sector momentum, which limits near-term upside for pure-play defense contractors.

18 total filings
· daily

Federal Professional Services Contracts — July 10, 2026

This digest covers a single, large civilian contract: a $189.3 million firm-fixed-price BPA call awarded to Guidehouse LLP by the Department of Veterans Affairs for management consulting services. The contract is fully funded but has zero outlayed dollars, indicating no revenue has been recognized yet, which creates a neutral signal. The award was competitive and not set aside, suggesting Guidehouse’s strength in the federal consulting market. Key risks include the medium pricing risk of a fixed-price contract and the need to monitor future outlays for revenue realization. No defense-related contracts are present, underscoring a purely civilian theme.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — July 10, 2026

Over the single-day period of July 10, 2026, federal IT and cybersecurity contracts totaled $73.2 million, with zero defense-related awards, highlighting a purely civilian procurement focus. The sole contract—a $73.2M delivery order to Booz Allen Hamilton from HHS/CMS for Marketplace System Integrator services—signals sustained investment in healthcare IT infrastructure, though execution risk arises from its labor-hours pricing structure. At a neutral signal strength of 5/10, the contract is a meaningful but non-transformative win for Booz Allen, with a potential ceiling of $354.4M through 2031. Key risks include a $19M subaward (26% of total) that reduces direct revenue and potential budget headwinds from future CMS appropriations. Investors should monitor Booz Allen's Q2 2026 earnings commentary on margin stability and option exercise catalysts tied to FY2027-2031 budget cycles.

1 total filings
· daily

All HHS Contracts — July 10, 2026

The three HHS contracts analyzed, totaling $195.5 million, are exclusively civilian awards with no defense exposure, reflecting sustained federal investment in health IT and biomedical research services. The highest-conviction signal is Leidos’ $87.1 million NIH NCI delivery order, which demonstrates competitive strength in life sciences R&D under a low-risk cost-plus-fixed-fee structure, though only 25% is funded to date. Booz Allen Hamilton’s $73.2 million CMS Marketplace System Integrator award (with potential $354.4 million ceiling) signals stable healthcare IT demand but carries medium execution risk due to labor-hours pricing. A key risk is the modest near-term revenue visibility across all contracts, as most funding is forward-looking and subject to option exercise or budget cycles.

3 total filings